首页> 外文期刊>BJU international >The long-term outcome of the endoscopic subureteric implantation of polydimethylsiloxane for treating vesico-ureteric reflux in children: a retrospective analysis of the first 195 consecutive patients in two European centres.
【24h】

The long-term outcome of the endoscopic subureteric implantation of polydimethylsiloxane for treating vesico-ureteric reflux in children: a retrospective analysis of the first 195 consecutive patients in two European centres.

机译:聚二甲基硅氧烷内镜下输尿管镜下植入治疗儿童膀胱输尿管返流的长期结果:对两个欧洲中心的前195名连续患者进行回顾性分析。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE To determine the long-term efficacy of endoscopically implanting polydimethylsiloxane (PDS, Macroplastique(R), Uroplasty BV, Geleen, the Netherlands) for treating vesico-ureteric reflux (VUR) in children. PATIENTS AND METHODS We retrospectively reviewed the records of 195 children treated with PDS over the past 10 years in two European centres (Netherlands and UK) and conducted follow-up investigations where deemed necessary. In the Dutch centre patients were treated according to a prospective approved study protocol. RESULTS Of the 195 treated children, 155 had a successful outcome; in all, 311 refluxing renal units were treated, with an overall success rate of 82.3% in a mixed group of patients with unilateral or bilateral VUR and duplex systems. CONCLUSION The long-term data from these two independent centres confirms the viability of PDS and the technique for treating VUR in children. We conclude that the material is safe and effective and can be used in VUR grades II-V. Treating patientswith grade I VUR is recommended in those cases where there is no spontaneous resolution and 'breakthrough' infections.
机译:目的确定内窥镜下植入聚二甲基硅氧烷(PDS,Macroplastique(R),Uroplasty BV,荷兰盖林)治疗儿童膀胱输尿管反流(VUR)的长期疗效。患者与方法我们回顾性回顾了过去10年中在两个欧洲中心(荷兰和英国)接受PDS治疗的195名儿童的记录,并在必要时进行了后续调查。在荷兰中心,根据前瞻性批准的研究方案对患者进行了治疗。结果在195名接受治疗的儿童中,有155名成功了。总共治疗了311个回流肾单位,在单侧或双侧VUR和双联系统患者的混合组中,总成功率为82.3%。结论来自这两个独立中心的长期数据证实了PDS的可行性以及治疗儿童VUR的技术。我们得出的结论是,该材料安全有效,可用于VUR II-V级。在没有自发性消退和“突破性”感染的情况下,建议治疗I级VUR患者。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号